Uniqure Announces Alignment With FDA On Accelerated Approval Pathway For AMT-130 In Huntington’S Disease
T-Reuters
2024-12-10
Uniqure :Uniqure Announces Alignment With Fda On Key Elements Of Accelerated Approval Pathway For Amt-130 In Huntington’S Disease.Uniqure Nv - Fda Agrees Cuhdrs May Serve As Intermediate Clinical Endpoint.Uniqure Nv - Fda Agrees Phase I/Ii Data May Serve As Basis For Bla.Uniqure Nv - Fda Agrees No Additional Pre-Submission Study Needed For Amt-130.